advanced medical technologies http://blog.mediligence.com insights, perspectives and inside data from medtech market analysis at MedMarket Diligence, LLC Wed, 27 Jul 2016 16:15:09 +0000 en-US hourly 1 Top Cardiovascular Surgical and Interventional Procedures, Projected to 2022 http://blog.mediligence.com/2016/07/26/top-cardiovascular-surgical-and-interventional-procedures-projected-to-2022/ Tue, 26 Jul 2016 14:29:36 +0000 http://blog.mediligence.com/?p=9471 Continue reading "Top Cardiovascular Surgical and Interventional Procedures, Projected to 2022"]]>

Below, after the categories of cardiovascular procedures, are the comprehensive listings of the surgical and interventional procedures in the management of cardiovascular disease represented in the MedMarket Diligence Report #C500, which also analyzes the clinical practice patterns, trends, and the impact on medical device sales and the impact of new medical device introductions during the forecast period, addressing each major area of surgical and interventional cardiovascular medicine:

  • AAA/TAA
  • Aneurysm AVM
  • Arrhythmia Ablation
  • CABG-PCI
  • Cardiac support
  • Carotid Cerebral Thrombectomy
  • CRM-IPG
  • DVT Thrombectomy
  • Endovenous Ablation
  • Heart Defect
  • Heart Valve
  • LAA Closure
  • LE Angio-Stent
  • Lower Extremity Atherectomy
  • Peripheral Artery Bypass
  • Peripheral Bypass
  • Peripheral Drug Balloon Angioplast
  • Vena Cava
  • Venous Stenting

We have sorted procedures first by growth (CAGR) to 2022, then by volume in 2022.

CV Procedures by Growth

Source: MedMarket Diligence, LLC; Report #C500.

CV Procedures by Volume

Source: MedMarket Diligence, LLC; Report #C500.

]]>
Sealant, Glues, Hemostat Sales to Surge in Asia-Pacific http://blog.mediligence.com/2016/07/25/sealant-glues-hemostat-sales-to-surge-in-asia-pacific/ Mon, 25 Jul 2016 21:04:22 +0000 http://blog.mediligence.com/?p=9468 Growth in Asia-Pacific sales of sealants, glues, and hemostats will outstrip growth in the larger U.S. market.

Screen Shot 2016-07-25 at 2.00.48 PM

Source: MedMarket Diligence, LLC; Report #S290.

]]>
Recent Merger and Acquisition Activity in Sealants, Glues and Hemostats http://blog.mediligence.com/2016/07/22/recent-merger-and-acquisition-activity-in-sealants-glues-and-hemostats/ Fri, 22 Jul 2016 20:01:06 +0000 http://blog.mediligence.com/?p=9463 Continue reading "Recent Merger and Acquisition Activity in Sealants, Glues and Hemostats"]]> Growth in sealants, glues, and hemostats markets has been strong enough for long enough to have attracted a lot of players. With growth slowing as the untapped potential is reducing more rapidly, consolidation has now appeared in the natural order of things.

Recent Merger and Acquisition Activity in Sealants, Glues and Hemostats

Original Company/ ProductAcquiring or Collaborating CompanyDate of Acquisition/Collaboration DealFinancial Details (where revealed)
Bristol-Myers Squibb/ Recothrom¨ Thrombin topical hemostatThe Medicines Company2012/2014$105 million collaboration fee
Cohera Medical/TissuGlu¨Collaboration with B. Braun Surgical S.A. to distribute in Germany, Spain and Portugal.Jan. 2015B. Braun Surgical S.A. will exclusively market and sell TissuGlu in the territories of Germany, Spain and Portugal through its existing Closure Technologies commercial teams.
Profibrix/ FibroCapsThe Medicines Company2013$90 million, with $140 million contingent upon milestones
Medafor/Arista¨ AH Absorbable Hemostatic ParticlesCR Bard (Bard Davol)2013$200 million upfront payment
Tenaxis Medical, with ArterX (among other products)The Medicines Company2014$58 million in upfront payments
The Medicines Company/ PreveLeakª (formerly known as ArterX), Raplixaª(formerly known as FibroCaps) fibrin sealant, Recothrom¨ Thrombin topical (Recombinant) sealantMallinckrodt plc2016The entire deal has a potential value of $410 million.
Xcede Technologies, Inc./Resorbable Hemostatic PatchCollaboration with Cook BiotechJan-16Signed three collaboration agreements with Cook Biotech, including a Development Agreement, a License Agreement and a Supply Agreement to complete development, seek regulatory clearance and produce XcedeÕs resorbable hemostatic patch.

Source: MedMarket Diligence, LLC; Report #S290.

]]>
Medtech old school: Ablation technologies http://blog.mediligence.com/2016/07/21/medtech-old-school-ablation-technologies/ Thu, 21 Jul 2016 23:21:28 +0000 http://blog.mediligence.com/?p=9456 Continue reading "Medtech old school: Ablation technologies"]]> Compared to the use of cellular based technologies, gene editing, nanotech, and even more promising technologies ahead, the technology of ablation — the use of simple energy at various wavelengths, at various temperatures, intensities, methods desigend to be effective, accurate, and precise —  is not as sexy, but these technologies really are medtech old school.

Indeed, ablation technologies may not be able to compete effectively against cell therapy, gene therapy, or other advanced medical technologies, especially where “cure” is a reality, but they really do stand at the forefront of surgery today (and in some sense as the likely peak of device technologies). They are not concepts or potential technologies, but are treating myriad diseases today, offering better outcomes and improving quality of lives and saving lives.

Growth rates in sales of devices, equipment, and supplies in most ablation types are at least respectable in an era of cost containment, while other ablation modalities are strong enough in tapping unmet patient demand that they are investment-attractive. Just as these technologies have emerged and developed alongside other MIS technologies, they will continue to track surgeries (or interventions, sorry cardio guys) and be there until surgery, interventional medicine, or whatever its moniker, is made obsolete.

See the Smithers Apex report, “The Future of Ablation Products to 2020,” described at link.

Screen Shot 2016-07-21 at 3.42.15 PM

Source: Smithers Apex

]]>
Medtech fundings for July 2016 http://blog.mediligence.com/2016/07/21/medtech-fundings-for-july-2016/ Thu, 21 Jul 2016 16:42:33 +0000 http://blog.mediligence.com/?p=9452 Continue reading "Medtech fundings for July 2016"]]> Medtech fundings for July 2016 stand at $550 million, led by the $183 million IPO of Bioventus, followed by the $32 million funding of Endotronix and the $30 million funding of Senseonics.

Below are the top fundings for the month thus far. Check back before month end to see updates.

Screen Shot 2016-07-21 at 9.39.02 AM

For a complete list of fundings in July 2016, see link.

]]>
Sealants, Glues, Hemostats development, markets globally in new report http://blog.mediligence.com/2016/07/19/sealants-glues-hemostats-development-markets-globally-in-new-report/ Wed, 20 Jul 2016 00:30:59 +0000 http://blog.mediligence.com/?p=9449 Worldwide Markets for Medical and Surgical Sealants, Glues, and Hemostats, 2015-2022.” Report #S290.

sealants graphic better

]]>
Fibrin and Other Sealants — Impacts of Emerging Market Growth http://blog.mediligence.com/2016/07/17/fibrin-and-other-sealants-impacts-of-emerging-market-growth/ Mon, 18 Jul 2016 01:26:17 +0000 http://blog.mediligence.com/?p=9445 Screen Shot 2016-07-17 at 6.19.22 PM

Source: MedMarket Diligence, LLC; Report #S290.

]]>
Hemostats doing relatively well to 2022 http://blog.mediligence.com/2016/07/13/hemostats-doing-relatively-well-to-2022/ Thu, 14 Jul 2016 06:36:22 +0000 http://blog.mediligence.com/?p=9441 Sales of hemostats will outpace products for sealing or adhesion of tissue, especially in Asia-Pacific.

Screen Shot 2016-07-13 at 11.28.58 PM

Source: MedMarket Diligence, LLC; Report #S290.

]]>
Growth of Surgical Sealants and Glues in Asia-Pacific http://blog.mediligence.com/2016/07/13/growth-of-surgical-sealants-and-glues-in-asia-pacific/ Wed, 13 Jul 2016 17:25:44 +0000 http://blog.mediligence.com/?p=9437 Screen Shot 2016-07-13 at 10.19.17 AM

Source: MedMarket Diligence, LLC; Report #S290.

]]>
Cardiovascular Surgical Procedures, Technologies Trended Globally to 2022 http://blog.mediligence.com/2016/07/06/cardiovascular-surgical-procedures-technologies-trended-globally-to-2022/ Wed, 06 Jul 2016 16:33:11 +0000 http://blog.mediligence.com/?p=9426 Continue reading "Cardiovascular Surgical Procedures, Technologies Trended Globally to 2022"]]> cardiovascular procedures

Global Dynamics of Surgical and Interventional Cardiovascular Procedures, 2015-2022. See Report #C500.

Publishing July 2016

This report covers surgical and interventional therapeutic procedures commonly used in the management of acute and chronic conditions affecting myocardium and vascular system. The latter include ischemic heart disease (and its life threatening manifestations like AMI, cardiogenic shock, etc.); heart failure; structural heart disorders (valvular abnormalities and congenital heart defects); peripheral artery disease (and limb and life threatening critical limb ischemia); aortic disorders (AAA, TAA and aortic dissections); acute and chronic venous conditions (such as deep venous thrombosis, pulmonary embolism and chronic venous insufficiency); neurovascular pathologies associated with high risk of hemorrhagic and ischemic stroke (such as cerebral aneurysms and AVMs, and high-grade carotid/intracranial stenosis); and cardiac rhythm disorders (requiring correction with implantable pulse generators/IPG or arrhythmia ablation).

The report offers current assessment and projected procedural dynamics (2015 to 2022) for primary market geographies (e.g., United States, Largest Western European Countries, and Major Asian States) as well as the rest-of-the-world.

See the complete table of contents at Report C500.

 

 

]]>
Abbott’s fully-absorbing stent gets FDA nod http://blog.mediligence.com/2016/07/05/abbotts-fully-absorbing-stent-gets-fda-nod/ Tue, 05 Jul 2016 20:54:36 +0000 http://blog.mediligence.com/?p=9422 Continue reading "Abbott’s fully-absorbing stent gets FDA nod"]]> AbsorbOUS-heroAbbott’s resorbable coronary stent, Absorb, gained FDA regulatory approval today, the first for a fully-dissolving coronary stent. Designed to be fully resorbed by the body within three years of implantation, the device is intended to achieve the endpoint of a more natural vasculature than can be achieved with metal stents.


In July 2016, MedMarket Diligence is publishing, “Global Dynamics of Surgical and Interventional Cardiovascular Procedures, 2015-2022”, Report #C500.

]]>
Fibrin, Thrombin, Collagen and Gelatin-Based Sealants, 2016 & 2022 http://blog.mediligence.com/2016/07/05/fibrin-thrombin-collagen-and-gelatin-based-sealants-2016-2022/ Tue, 05 Jul 2016 16:15:08 +0000 http://blog.mediligence.com/?p=9405 fibrin2016

Source: MedMarket Diligence, LLC; Report #S290 (July 2016).

fibrin2022

Source: MedMarket Diligence, LLC; Report #S290 (July 2016).

collagen2016

Source: MedMarket Diligence, LLC; Report #S290 (July 2016).

collagen2022

Source: MedMarket Diligence, LLC; Report #S290 (July 2016).

]]>
June 2016 medtech fundings http://blog.mediligence.com/2016/06/26/june-2016-medtech-fundings/ Mon, 27 Jun 2016 02:00:15 +0000 http://blog.mediligence.com/?p=9392 Continue reading "June 2016 medtech fundings"]]> Medtech fundings for June 2016 stand at $607 million, led by the $172.5 million post-IPO sale of Nevro’s convertible notes, the $75 million IPO (to happen in June) of OrthoPediatrics, and the $50 million funding of Clearside Biomedical.

Below are fundings for the month, thus far. Please revisit this post (and refresh your browser) for updates by month-end.

Screen Shot 2016-06-27 at 11.57.31 AM

For a complete list of fundings during June 2016.

]]>
Where is the medtech growth? http://blog.mediligence.com/2016/06/22/where-is-the-medtech-growth/ Wed, 22 Jun 2016 20:58:45 +0000 http://blog.mediligence.com/?p=9386 Continue reading "Where is the medtech growth?"]]> Medical technology is, for many of its markets, being forced to look for growth from more sources, including emerging markets. Manufacturers are able to gain better margins through innovation, but their success varies by clinical application.

Cardiology. A demanding patient base (it’s life or death). Be that as it may, there are few new or untapped markets, only the opportunity for new technologies to displace existing markets. Interventional technologies are progressively enabling treatment of larger patient populations, but much growth will still be from emerging markets.

Wound management. Even the most well-established markets will see growth from innovation. The wound market just needs less growth to be happy, since small percentage growth becomes very large by volume. And yet, some of the most significant growth in the long run will be for more advanced

Surgery. Every aspect of surgery seems to be subject to attempts to improve upon it. Robotics, endoscopy, transcatheter, single-port, incisionless, natural orifice. Interventional options are increasing the treatable patient population, and it seems likely that continued development (e.g., materials, including biodegradables, use of drug or other coatings, including cells) will yield more routine procedures for more and different types of conditions, many of which have been inadequately served, if it all.

Orthopedics. Aging populations demanding more agility and mobility will drive orthopedic procedures and device use. Innovation still represents some upside, but more from 3D printing than other new technologies being introduced to practice.

Tissue/Cell Therapy. This is a technology opportunity (and represents radical innovation for most clinical areas), but it is also a set of target clinical applications, since tissues/cells are being engineered to address tissue or cell trauma or disease. Growth is displacing existing markets with new technology, such as bioengineered skin, tendons, bladders, bone, cardiac tissue, etc. These are fundamentally radical technologies for the target applications.

Below is my conceptual opinion on the balance of growth by clinical area coming from routine innovation (tweaks, improvements), radical innovation (whole new “paradigms” like cell therapy in cardiology), and emerging market growth (e.g., China, S. America).

Screen Shot 2016-06-22 at 1.56.13 PM

Source: MedMarket Diligence, LLC, opinion!

]]>
Transcath and surgical cardio volumes trending http://blog.mediligence.com/2016/06/14/transcath-and-surgical-cardio-volumes-trending/ Tue, 14 Jun 2016 20:49:10 +0000 http://blog.mediligence.com/?p=9380 Continue reading "Transcath and surgical cardio volumes trending"]]> VasculatureInterventional devices, offering MIS advantages, have preempted surgical caseload, and have expanded the treatable patient population. Multiple competitive alternatives are effective for high volume procedures for treatment of coronary artery, peripheral artery and other cardiovascular pathologies.

Clinicians have changing demands, sometimes very much in alignment with what manufacturers see as needs (it is good to point out their need before they see it).

Older populations are good for medtech — let’s be honest. (Yes, the “aging demographic” argument has been made again, but it is particularly true for interventional procedures, which are used disproportionately in older populations in accordance with age-based incidence rates in cardiovascular disorders.)

Cardio device manufacturers both lead and follow the market. Technologies that lower invasiveness, reduce complications, reduce repeats, increase outcomes, lower costs, and provide other benefits drive new procedure volume. When new technologies are progressively introduced, they have variable impacts on procedure volume, either displacing caseload or tapping new. The timing and relative impact of new technology emerging can cause abrupt shifts in caseload, procedures — and revenue.

Here are the top procedures for surgical and interventional cardiology:

  • Coronary artery bypass grafting
  • Coronary angioplasty and stenting coronary/mechanical and laser atherectomy
  • Ventricular assist device placement
  • Total artificial heart implantation
  • Donor heart transplantation
  • Lower extremity arterial bypass surgery
  • Percutaneous transluminal angioplasty (PTA) and bare metal stenting
  • PTA and drug-eluting stenting
  • PTA with coated balloons
  • Mechanical and laser atherectomy
  • Catheter-directed thrombolysis and thrombectomy
  • Aortic aneurysm repair
  • Vena cava filter placement
  • Endovenous ablation
  • Mechanical venous thrombectomy
  • Venous angioplasty and stenting
  • Carotid endarterectomy
  • Carotid artery stenting
  • Cerebral thrombectomy
  • Cerebral aneurysm and AVM surgical clipping
  • Cerebral aneurysm and AVM coiling & flow diversion
  • Congenital heart defect repair
  • Heart valve repair and replacement surgery
  • Transcatheter valve repair and replacement
  • Pacemaker implantation
  • Implantable cardioverter defibrillator placement
  • Cardiac resynchronization therapy device placement
  • Standard SVT ablation
  • Surgical AFib ablation
  • Transcatheter AFib ablation

These procedures are the subject of a June 2016 report from MedMarket Diligence, “Global Dynamics of Surgical and Interventional Cardiovascular Procedures, 2015-2022” (report #C500).

]]>
Sealants, Glues, Hemostats to 2022 http://blog.mediligence.com/2016/06/08/sealants-glues-hemostats-to-2022/ Wed, 08 Jun 2016 17:35:54 +0000 http://blog.mediligence.com/?p=9375 Continue reading "Sealants, Glues, Hemostats to 2022"]]>  

Below is our bubble chart giving the segment size (bubble size and horizontal axis position) and growth (vertical axis position) of the products detailed in our 2014 report #S192.

Source: MedMarket Diligence, LLC; Report #S192 (published Oct. 2014)

Given the interest by companies actively involved in sealants, glues, and hemostats, we are publishing Report #S290 (June 2016), “Worldwide Markets for Medical and Surgical Sealants, Glues, and Hemostats, 2015-2022.”

From Skitch

]]>
What is the ideal wound product? http://blog.mediligence.com/2016/06/06/what-is-the-ideal-wound-product/ Tue, 07 Jun 2016 01:26:27 +0000 http://blog.mediligence.com/?p=9365 Continue reading "What is the ideal wound product?"]]> The previously accepted wisdom was that a wound healed best when it was kept as dry as possible. In 1962, George Winter, a British-born physician, published his ground-breaking wound care research. His paper, (Nature 193:293. 1962), entitled, “Formation of the scab and the rate of epithelization of superficial wounds in the skin of the young domestic pig,” demonstrated that wounds kept moist healed faster than those exposed to the air or covered with a traditional dressing and kept dry. Dr. Winter’s work began the development of modern wound dressings which are used to promote moist wound healing.

Natural skin is considered the ideal wound dressing, and therefore wound dressings have been designed to try to reproduce the advantages of natural skin. Today, experts feel that a wound dressing should have several characteristics if it is to serve its purpose. A wound dressing should:

  • Provide the optimal moisture needs for the particular wound
  • Have the capacity to provide thermal insulation, gaseous exchange, and to help drainage and debris removal, which promotes tissue reconstruction
  • Be biocompatible without causing any allergic or immune response reaction
  • Protect the wound from secondary infections
  • Be easily removable without causing any trauma to the delicate healing tissues.

There are hundreds of dressings to choose from, but they all fall into one of a few categories. The healthcare provider will select a dressing by category, according to availability and familiarity of using that particular dressing.

Occlusive dressings are those which are air- and water-tight. An occlusive dressing is frequently made with some kind of waxy coating to ensure a totally water-tight bandage. It may also consist of a thin sheet of plastic affixed to the skin with tape. An occlusive dressing retains moisture, heat, body fluids and medication in the wound. There are several types of occlusive dressings, which are discussed below.

It should be remembered that proper wound care, especially of a chronic wound, is a complex process, as much art as science; a trained healthcare provider assesses the wound as it goes through various stages, and applies the appropriate wound dressings as the need arises. Unfortunately, the most appropriate dressing is not always used, due perhaps to confusion around which type of dressing to apply, or because certain dressings—especially advanced dressings—either may not be available in the facility, or may not be reimbursed by the country’s healthcare system, or may simply be too expensive. This remains true even in some of the developed countries.

The following table summarizes potential applications for various types of wound care products, with selected examples. This summary is meant as a guideline and an illustration of the fact that different dressing types may find use in various types of wounds. In addition, as a wound heals, it may need a different type of dressing. Here again the wound care professional’s judgment and training come into play.

Dressing categoryProduct examplesDescriptionPotential applications
FilmHydrofilm, Release, Tegaderm, BioclusiveComes as adhesive, thin transparent polyurethane film, and as a dressing with a low adherent pad attached to the film.Clean, dry wounds, minimal exudate; also used to cover and secure underlying absorptive dressing, and on hard-to-bandage locations, such as heel.
FoamPermaFoam, PolyMem, BiatainPolyurethane foam dressing available in sheets or in cavity filling shapes. Some foam dressing have a semipermeable, waterproof layer as the outer layer of the dressingFacilitates a moist wound environment for healing. Used to clean granulating wounds which have minimal exudate.
HydrogelHydrosorb Gel Sheet, Purilon, Aquasorb, DuoDerm, Intrasite Gel, Granugel,Colloids which consist of polymers that expand in water. Available in gels, sheets, hydrogel-impregnated dressings.Provides moist wound environment for cell migration, reduces pain, helps to rehydrate eschar. Used on dry, sloughy or necrotic wounds.
HydrocolloidCombiDERM, Hydrocoll, Comfeel, DuoDerm CGF Extra Thin, Granuflex, TegasorbÕ Nu-DermMade of hydroactive or hydrophilic particles attached to a hydrophobic polymer. The hydrophilic particles absorb moisture from the wound, convert it to a gel at the interface with the wound. Conforms to wound surface; waterproof and bacteria proof.Gel formation at wound interface provides moist wound environment. Dry necrotic wounds, or for wounds with minimal exudate. Also used for granulating wounds.
AlginateAlgiSite, Sorbalgon Curasorb, Kaltogel, Kaltostat, SeaSorb, TegagelA natural polysaccharide derived from seaweed; available in a range of sizes, as well as in ribbons and ropes.Because highly absorbent, used for wounds with copious exudate. Can be used in rope form for packing exudative wound cavities or sinus tracts.
AntimicrobialBiatain Ag, Atrauman Ag, MediHoneyBoth silver and honey are used as antimicrobial elements in dressings.Silver: Requires wound to be moderately exudative to activate the silver, in order to be effective
NPWDSNaP, V.A.C. Ulta, PICO, Renasys (not in USA), Prospera PRO series, Invia LibertyComputerized vacuum device applies continuous or intermittent negative or sub-atmospheric pressure to the wound surface. NPWT accelerates wound healing, reduces time to wound closure. Comes in both stationary and portable versions.May be used for traumatic acute wound, open amputations, open abdomen, etc. Seems to increase burn wound perfusion. Also used in management of DFUs. Contraindicated for arterial insufficiency ulcers. Not to be used if necrotic tissue is present in over 30% of the wound.
Bioengineered Skin and Skin SubstitutesAlloDerm, AlloMax, FlexHD, DermACELL, DermaMatrix, DermaPure, Graftjacket Regenerative Tissue Matrix, PriMatrix, SurgiMend PRS, Strattice Reconstructive Tissue Matrix, Permacol, EpiFix, OASIS Wound Matrix, Apligraf, Dermagraft, Integra Dermal Regeneration Template, TransCyteBio-engineered skin and soft tissue substitutes may be derived from human tissue (autologous or allogeneic), xenographic, synthetic materials, or a composite of these materials.Burns, trauma wounds, DFUs, VLUs, pressure ulcers, postsurgical breast reconstruction, bullous diseases

Source: MedMarket Diligence, LLC; Report #S251.

]]>
Growth in Advance Wound Care Product Revenues, 2014 to 2024 http://blog.mediligence.com/2016/06/05/growth-in-advance-wound-care-product-revenues-2014-to-2024/ Mon, 06 Jun 2016 04:16:01 +0000 http://blog.mediligence.com/?p=9358 Continue reading "Growth in Advance Wound Care Product Revenues, 2014 to 2024"]]> Even excluding the three traditional wound care dressing segments, the advanced wound care market is enormous — over the next ten years, it will grow at a compound annual growth rate of at least 7.7%, and is forecast to reach nearly $16 billion by 2024. This market is being driven by several inter-related factors: the increasing percentage of the aged (65years old and over) in country populations, the fact that people are living longer, obesity, the virtually epidemic rise of Type 2 diabetes, government policies intended to curb healthcare spending, and an increasingly sedentary population. The latter trend is seen especially in developed countries, but is also on the rise in less-developed countries as their economic standing improves and the middle class grows in numbers.

Certain product segments are forecast to have stronger growth than others. Sales of bioengineered skin & skin substitutes for wound care will increase at a CAGR of at least 15%, while sales of foam and hydrocolloid dressings will be growing at high single-digit rates, respectively.

Advance Wound Care Product Revenues, 2014 to 2024

Wound 2014 and 2024

Source: MedMarket Diligence, LLC; Report #S251.

]]>
Medtech fundings for June 2016 http://blog.mediligence.com/2016/06/03/medtech-fundings-for-june-2016/ Fri, 03 Jun 2016 23:14:26 +0000 http://blog.mediligence.com/?p=9353 Below are the top medtech fundings for June 2016 to date. Revisit this post, or go to link, to see additional fundings in June.

Screen Shot 2016-06-03 at 3.54.22 PM

For a historical listing of medtech fundings by month, see link.

]]>
Cerebral Aneurysm and AVM Embolization Systems http://blog.mediligence.com/2016/06/03/cerebral-aneurysm-and-avm-embolization-systems/ Fri, 03 Jun 2016 20:28:19 +0000 http://blog.mediligence.com/?p=9349 Continue reading "Cerebral Aneurysm and AVM Embolization Systems"]]> The ultimate objective of cerebral endovascular embolization is to hemoisolate rupture-prone or ruptured neurovascular abnormality from cerebral circulation with the view of preventing major primary or secondary hemorrhage into intracranial space. Technically, cerebrovascular embolization is accomplished through a transcatheter deployment of one or several embolizing agents into the unstable aneurysmal sac or AVM’s fundus in the amount sufficient for eventually arresting an internal blood flow and prompting lesion obliteration.

In cases involving large, giant and wide neck aneurysms, stent-assisted coiling or coil-free flow diversion device-based embolization are typically utilized.

Cerebral endovascular embolization systems include microcoils and liquid embolics with associated transcatheter delivery devices (e.g., micro guidewires, microcatheters, etc.), as well as coil-containing stents and flow diversion devices.

In recent years, transcatheter embolization techniques have emerged as a mainstay treatment modality in repair of rupture-prone cerebral aneurysms and indispensable presurgical adjunct in treatment of intracranial AVMs.

Aside from the ongoing (but gradually moderating in the U.S. Europe and Japan) migration of patients from open surgical to minimally invasive neurovascular embolization techniques, consistent and robust growth in this market was driven by the introduction of improved and premium-priced embolic coil designs, launch of coil containing stents for wide neck aneurysms, and increasing utilization of user-friendly liquid embolics in AVM (and selected wide neck aneurysm) applications.

In the forthcoming years, the cited growth factors are likely to stay in place supporting further expansion of cerebral aneurysm and AVM transcatheter embolization business.

In 2014, endovascular embolization techniques were employed in approximately 90.5 thousand cerebral aneurysm and AVM repair procedures worldwide, of which aneurysm targeting interventions accounted for about 89.2%, with the rest contributed by AVMs hemoisolation.

Cumulative global sales of cerebral endovascular embolization products were estimated at about $851 million in 2014, of which U.S. accounted for $339.8 million (or 39.9%), followed by the largest Western European states with 242.1 million (or 28.5%), major Asian-Pacific states with $178.9 million (or 21.1%), and the rest-of-the-world with the remaining $89.4 million (or 10.5% of the total).

During the forecast period, the total global volume of transcatheter neurovascular embolization procedures is projected to grow 4% per annum to an estimated 109.9 thousand interventions in the year 2019. The largest absolute and relative gains in cerebral embolization procedure volumes are expected in the largest Asian-Pacific states (mostly China) and the Rest-of-the-World, where low relative usage of endovascular techniques (30-35% versus 65-75% in the U.S. and Europe) will continue to support their increasing penetration of clinical practices and serve as the primary locomotive of growth in the corresponding global product market. Largely mature U.S. and West European market geographies are likely to register considerably more modest advances in cerebral embolization procedure volumes.

The worldwide sales of cerebral aneurysm and AVM embolization products are forecast to expand at a slightly slower 3.6% average annual rate to an estimated $1,017 million in the year 2019. The largest relative and absolute gains in the market can be expected in the flow diversion system segment which is projected to grow an average of 20.7% annually and add over $96 million in product sales to a total of $157.7 by 2019.

Geographically, grossly underpenetrated Asian-Pacific and ROW markets are likely to register the fastest growth expanding 7.1% and 7.6% per annum to approximately $253.3 million and $128.9 million in 2019, accordingly.


From, “Emerging Global Market for Neurointerventional Technologies in Stroke, 2014-2019,” Report #C310.

]]>